乳糖吸收不良与不耐受:发病机制、诊断与临床管理更新
本文综述乳糖吸收不良(LM)与乳糖不耐受(LI)的发病机制、诊断与临床管理。乳糖酶缺乏(LD)由LCT基因-13'910位点C→T多态性介导,LM包括原发性和继发性,LI指LM个体摄入乳糖后出现腹痛、腹胀和腹泻。诊断包括基因、内镜和生理学检查,治疗包括低乳糖饮食、乳糖酶补充和益生元结肠适应,但临床效果有限。
要点
- 乳糖酶缺乏由LCT基因-13'910位点C→T多态性介导。
- LI指LM个体摄入乳糖后出现腹痛、腹胀和腹泻。
- LI可能性取决于乳糖剂量、乳糖酶表达和肠道菌群。
核心结论
- 乳糖不耐受的临床结局取决于乳糖剂量、乳糖酶表达和肠道菌群,治疗措施效果有限。
- 乳糖仅是多种吸收不良碳水化合物之一,可通过类似机制引起症状。
研究设计与样本
- 本文为综述,检索范围未在原文中报告。
主要发现
- 乳糖酶持久性遗传机制由LCT基因-13'910位点C→T多态性介导。
- LM包括原发性遗传性和继发性乳糖酶缺乏。
- LI可能性取决于乳糖剂量、乳糖酶表达和肠道菌群。
- 内脏高敏感伴焦虑或IBS患者LI风险增加。
- 自报LI、客观发现与饮食干预临床结局之间关联可变。
关键数值与推荐
- 乳糖酶持久性遗传机制由LCT基因-13'910位点C→T多态性介导。
- LI定义为LM个体摄入乳糖后出现腹痛、腹胀和腹泻。
- 诊断检查包括基因、内镜和生理学检查。
- 治疗包括低乳糖饮食、乳糖酶补充和益生元结肠适应。
临床怎么用
- 诊断LM和LI可选用基因、内镜和生理学检查。
- 治疗LI可包括低乳糖饮食、乳糖酶补充和益生元结肠适应。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lactose is the main source of calories in milk, an essential nutriedigestion, patients with visceral hypersensitivity nt in infancy and a key part of the diet in populations that maintain the ability to digest this disaccharide in adulthood. Lactase deficiency (LD) is the failure to express the enzyme that hydrolyses lactose into galactose and glucose in the small intestine. The genetic mechanism of lactase persistence in adult Caucasians is mediated by a single C→T nucleotide polymorphism at the LCTbo -13'910 locus on chromosome-2. Lactose malabsorption (LM) refers to any cause of failure to digest and/or absorb lactose in the small intestine. This includes primary genetic and also secondary LD due to infection or other conditions that affect the mucosal integrity of the small bowel. Lactose intolerance (LI) is defined as the onset of abdominal symptoms such as abdominal pain, bloating and diarrhoea after lactose ingestion by an individual with LM. The likelihood of LI depends on the lactose dose, lactase expression and the intestinal microbiome. Independent of lactose digestion, patients with visceral hypersensitivity associated with anxiety or the Irritable Bowel Syndrome (IBS) are at increased risk of the condition. Diagnostic investigations available to diagnose LM and LI include genetic, endoscopic and physiological tests. The association between self-reported LI, objective findings and clinical outcome of dietary intervention is variable. Treatment of LI can include low-lactose diet, lactase supplementation and, potentially, colonic adaptation by prebiotics. The clinical outcome of these treatments is modest, because lactose is just one of a number of poorly absorbed carbohydrates which can cause symptoms by similar mechanisms.
引用
- Misselwitz B, Butter M, Verbeke K, et al. Update on lactose malabsorption and intolerance: pathogenesis, diagnosis and clinical management. Gut. 2019. PMID: 31427404. doi:10.1136/gutjnl-2019-318404
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。